A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

NCT01493336 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer, Colorectal Cancer

Interventions

DRUG: capecitabine RTD
DRUG: capecitabine [Xeloda]
DRUG: capecitabine [Xeloda]

Sponsor

Hoffmann-La Roche